Mark K. Ferguson to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Mark K. Ferguson has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
3.287
-
Small Modifications in Technique May Yield Large Rewards After Lung Cancer Surgery. JAMA Surg. 2019 07 01; 154(7):e191014.
Score: 0.371
-
Does Race Influence Risk Assessment and Recommendations for Lung Resection? A Randomized Trial. Ann Thorac Surg. 2018 10; 106(4):1013-1017.
Score: 0.345
-
Lymphovascular invasion as a prognostic indicator in stage I non-small cell lung cancer: a systematic review and meta-analysis. Ann Thorac Surg. 2014 Mar; 97(3):965-71.
Score: 0.254
-
Predicted postoperative lung function is associated with all-cause long-term mortality after major lung resection for cancer. Eur J Cardiothorac Surg. 2014 Apr; 45(4):660-4.
Score: 0.249
-
Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. Ann Thorac Surg. 2013 Mar; 95(3):1112-21.
Score: 0.238
-
Invited commentary. Ann Thorac Surg. 2007 Sep; 84(3):981.
Score: 0.164
-
Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg. 2003 Dec; 76(6):1782-8.
Score: 0.126
-
Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis. J Thorac Cardiovasc Surg. 2003 Dec; 126(6):1935-42.
Score: 0.126
-
STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273.
Score: 0.118
-
Lung resection surgery in Jehovah's Witness patients: a 20-year single-center experience. J Cardiothorac Surg. 2022 Oct 20; 17(1):272.
Score: 0.117
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.109
-
Does pneumonectomy for lung cancer adversely influence long-term survival? J Thorac Cardiovasc Surg. 2000 Mar; 119(3):440-8.
Score: 0.097
-
Effect of Endoscopic Bronchial Ultrasound on Outcomes for Stage I Non-Small-Cell Lung Cancer Patients Receiving Hypofractionated Radiotherapy. Clin Lung Cancer. 2018 03; 19(2):e227-e233.
Score: 0.082
-
Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2017 Aug; 44(8):1275-1284.
Score: 0.079
-
Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer. Nucl Med Commun. 2017 Feb; 38(2):185-192.
Score: 0.079
-
Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy. Technol Cancer Res Treat. 2017 02; 16(1):15-21.
Score: 0.075
-
Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86.
Score: 0.074
-
Thoracic Revised Cardiac Risk Index Is Associated With Prognosis After Resection for Stage I Lung Cancer. Ann Thorac Surg. 2015 Jul; 100(1):195-200.
Score: 0.070
-
Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol. 2013 Jul; 8(7):915-22.
Score: 0.061
-
American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest. 2012 Dec; 142(6):1620-1635.
Score: 0.059
-
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):446-50.
Score: 0.053
-
MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.
Score: 0.052
-
Does induction treatment increase the risk of morbidity and mortality after pneumonectomy? A multicentre case-matched analysis. Eur J Cardiothorac Surg. 2010 Mar; 37(3):535-9.
Score: 0.049
-
Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. Arch Pathol Lab Med. 2008 Dec; 132(12):1882-8.
Score: 0.045
-
Diffusing capacity predicts morbidity after lung resection in patients without obstructive lung disease. Ann Thorac Surg. 2008 Apr; 85(4):1158-64; discussion 1164-5.
Score: 0.043
-
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008 Jan; 3(1):59-67.
Score: 0.042
-
Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. Am J Clin Oncol. 2007 Jun; 30(3):258-63.
Score: 0.040
-
Concomitant chemoradiotherapy for non-small cell lung cancer. Lung Cancer. 1994 Mar; 10 Suppl 1:S253-61.
Score: 0.016
-
The impact on survival by adjuvant chemotherapy and radiation therapy in stage II non-small-cell lung cancer. Am J Clin Oncol. 1992 Oct; 15(5):405-11.
Score: 0.015
-
5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non-small cell lung cancer. Cancer. 1990 Aug 01; 66(3):437-42.
Score: 0.013
-
Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990 Aug; 8(8):1402-7.
Score: 0.013
-
Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. Chest. 1989 Jul; 96(1):110-3.
Score: 0.012
-
A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. Cancer Chemother Pharmacol. 1995; 35(4):304-12.
Score: 0.004